Take­da fo­cus­es on ‘di­verse’ pipeline prospects on heels of two ac­qui­si­tions

Af­ter a whop­ping $4 bil­lion as­set buy from Nim­bus Ther­a­peu­tics, along with a $400 mil­lion deal with Hutchmed for a col­orec­tal can­cer drug, Take­da ex­ec­u­tives tout­ed pipeline op­ti­mism on its lat­est earn­ings call this week.

That’s be­cause the TYK2 in­hibitor for pso­ri­a­sis Take­da is get­ting from Nim­bus, along with the Hutchmed fruquin­tinib com­mer­cial­iza­tion out­side of Chi­na, are just two of what it re­ports are 10 late-stage de­vel­op­ment pro­grams of promis­ing can­di­dates.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER